News

In this week’s Pointers with Portela, the 208SkinDoc explains his recommendations for effective products to buy to start a skin care routine.

Cameron Dermatology, which just opened in NYC, will address both medical and cosmetic issues.

In part 4 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

Researchers conducted a systematic review of pediatric melanoma.

Cryoanesthesia was safe and reduced pain in patients receiving intralesional triamcinolone steroid injections.

This week's edition of the Mainstream Patient features stories about 8 Black-owned holistic beauty brands, tear trough filler for under-eye bags, dermatologist-approved SPF-containing moisturizers, and more.

Click here to answer this week's poll.

Learn more about the in-depth topics covered in the May 2023 issue of Dermatology Times®.

In this month’s Legal Eagle column, we delve into cases involving informed consent.

This Memorial Day, the Dermatology Times® team is taking the time to spotlight dermatologic disparities and concerns among veterans and active members of the military.

Learn from a panel of sun protection experts on how to effectively prepare your patients for the summer sun.

ICYMI, this week we had stories about more adalimumab biosimilars, brepocitinib for psoriatic arthritis, sunscreen screenings for veterans, and more.

In patients with high levels of VEGF-A and more severe psoriasis, downregulation of blood vessel area is more abrupt.

Coastal regions require environmentally-protective sun protection measures and best practices.

In this month’s Finance & Practice Management column, we illustrate the importance of developing and maintaining a budget for physicians at all stages of their careers.

This week's edition of the Mainstream Patient features stories about facial balancing, eyelid surgery 101, dermatologist-recommended sunscreen sticks, and more.

The clinical and histologic subtypes encompassed by granulomatous dermatitis include palisaded neutrophilic granulomatous dermatitis and interstitial granulomatous dermatitis. This review compares the features of each cutaneous eruption.

Yuflyma will be available to US patients in July 2023.

The JAK inhibitor demonstrated promising efficacy and safety.

Click here to answer this week's poll.

While receiving checkpoint inhibitor therapy, patients with advanced melanoma benefitted from a telehealth exercise program.

The autosomal recessive disorder is primarily caused by mutations in the TGM5 gene and less frequently in the CSTA gene.

In this week’s Pointers with Portela, the 208SkinDoc gives his best product recommendations for Mother's Day gifts.

If you weren’t able to attend SCALE 2023 or want to review the latest data, our full recap has you covered.

Cream containing epigallocatechin gallate (EGCG) or EGCG combined with L-carnitine yielded a greater anti-sebum effect.

New research into the disease’s pathogenesis may inform future treatment options.

In part 3 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

The first-of-a-kind product uses a topically applied small peptide fluorescent dye and handheld imager to non-invasively detect a biomarker of early tissue changes.

The adalimumab biosimilar will be commercially available in the US starting July 1, 2023.

Topline results for the topical sodium channel blocker are expected in 2024.